Drugs / XytriX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07487766 | May 2026 → May 2027 expected | osteoarthritis, knee | TricelX Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-23 | TricelX Inc. | Regulatory TriCelX Receives FDA Study May Proceed Letter for XytriX™ tricelx.com ↗ |
| 2026-03-30 | TricelX Inc. | Regulatory TriCelX Files IND with FDA & Concurrently Requests RMAT Designation for XytriX™ in the Treatment of Knee Osteoarthritis tricelx.com ↗
IND Filing and Concurrent RMAT Request Position XytriX™ as a Potential Breakthrough Biotherapeutic for More Than 500 Million People Living with Osteoarthritis. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-23 | TricelX Inc. | TriCelX Receives FDA Study May Proceed Letter for XytriX™ tricelx.com ↗ |
| 2026-03-30 | TricelX Inc. | TriCelX Files IND with FDA & Concurrently Requests RMAT Designation for XytriX™ in the Treatment of Knee Osteoarthritis tricelx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XytriX | “The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis” NCT07487766 ↗ |
| Modality | Cell therapy | “XytriX, an umbilical cord-derived stem cell product” NCT07487766 ↗ |